ASCENT demonstrated the efficacy of Sacituzumab govitecan (SG) in patients (pts) with metastatic triple-negative breast cancer (mTNBC), and led to EMA approval in November 2021.
We set up an ambispective bicentric cohort study to assess the real-world effectiveness and safety of SG in pts with mTNBC. This study included pts treated through the French Early Access Program from May 2021 to January 2023. Pts provided written consent for their clinical data to be reported.
The cohort included 103 pts with a median age of 55 years [26-89]; 7/74 pts (9%) had BRCA1/BRCA2 germline mutation, 15 pts (15%)
Our real-world data in mTNBC pts are consistent with results of the ASCENT trial in terms of ORR and safety, but observed PFS and OS are numerically shorter, including pts with brain metastases.
Institut Curie.
Has not received any funding.
D. Loirat: Financial Interests, Personal, Advisory Board, Travel expenses, Honoraria: MSD, Novartis, AstraZeneca; Financial Interests, Personal, Advisory Board, Honoraria: Lilly; Financial Interests, Institutional, Advisory Board, Travel expenses,: Gilead; Financial Interests, Personal, Other, Travel expenses, Honoraria: Pfizer; Financial Interests, Personal, Other, Honoraria, Travel expenses: Seagen, Exact Sciences; Financial Interests, Personal, Other, Honoraria: EISAI. L. Escalup: Financial Interests, Personal, Advisory Board: Mylan. P. Vaflard: Financial Interests, Personal, Advisory Role: Gilead. P.H. Cottu: Financial Interests, Personal, Advisory Board, Travel/Accomodation, honoraria: Pfizer, Roche/Genentech; Financial Interests, Personal, Advisory Board, honoraria: Lilly; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant, honoraria: Pfizer; Financial Interests, Personal, Other, honoraria: Seagen, NanoString Technologies, Pierre Fabre. J. Pierga: Financial Interests, Personal, Advisory Board, Honoraria, Travel expenses: Roche/Genentech, Novartis, Pfizer, AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Advisory Board, HonorariaTravel expenses: Lilly; Financial Interests, Personal, Advisory Board: AbbVie, MSD, Seattle Genetics, Eisai, Pierre Fabre Oncologie; Financial Interests, Personal, Advisory Board, Honoraria: Gilead. All other authors have declared no conflicts of interest.